IE 11 is a very old Browser and it`s not supported on this site

loading

Get an in-depth insight of one of the leading biotech investors

graphic

«Healthcare markets rebounded from the April sell-off to close the second quarter in positive territory»

Dr. Erich Hunziker

Chairman

Shareholder letter

Interview Head Investment Team

The corona pandemic continues to hold the world in its grip. The biotech industry, on the other hand, is additionally moved by a new drug, the Alzheimer's drug Aduhelm from Biogen. A few weeks ago, this drug received FDA approval in June of this year. Find out more in a conversation with Dr. Daniel Koller, Head Investment Team, on the occasion of the half-year figures of BB Biotech AG 2021.

To the inteRView
graphic

Investment strategy

BB Biotech invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. It focuses on biotech companies whose products address areas of significant unmet medical needs and thus have above-average sales and profit-growth potential. 

To the Strategy

Performance

BB BIOTECH (SIX)

CHF 87.00

30.06.2021

Market capitalisation

CHF 4.8 bn

Net Asset Value (NAV)

CHF 73.05

Premium

19.1%

BB BIOTECH (XETRA)

EUR 79.25

30.06.2021

Market capitalisation

EUR 4.4 bn

Net Asset Value (NAV)

EUR 66.60

Premium

19.0%

BB BIOTECH (STAR)

EUR 79.20

30.06.2021

Market capitalisation

EUR 4.4 bn

Net Asset Value (NAV)

EUR 66.60

Premium

18.9%

To the PERFORMANCE

Portfolio

Moderna

12.2%

30.06.2021

IONIS PHARMACEUTICALS

7.7%

30.06.2021

ARGENX SE

6.1%

30.06.2021

NEUROCRINE BIOSCIENCES

6.0%

30.06.2021

Incyte

5.2%

30.06.2021

Agios Pharmaceuticals

5.0%

30.06.2021

Fate Therapeutics

4.7%

30.06.2021

VERTEX PHARMACEUTICALS

4.5%

30.06.2021

prev
next
To the Portfolio

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer